Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Biocordcell Argentina begins bone marrow stem cell storage services prior to cancer surgeries

Biocordcell Argentina begins bone marrow stem cell storage services prior to cancer surgeries

Research shows numerous health benefits of Modified Citrus Pectin

Research shows numerous health benefits of Modified Citrus Pectin

Ecstasy redesigned for use against blood cancer

Ecstasy redesigned for use against blood cancer

BancoVida, CBAI partner to offer umbilical cord blood collection services in Puerto Rico

BancoVida, CBAI partner to offer umbilical cord blood collection services in Puerto Rico

Nature Medicine publishes research on leukemia stem cells

Nature Medicine publishes research on leukemia stem cells

Severe combined immunodeficiency treated successfully with gene therapy

Severe combined immunodeficiency treated successfully with gene therapy

NeoStem featured on CBS's Eye on New York City

NeoStem featured on CBS's Eye on New York City

Long-term effects of chemotherapy on women's reproductive health

Long-term effects of chemotherapy on women's reproductive health

Researchers discover NPC1 protein as crucial for Ebola virus to enter host cells

Researchers discover NPC1 protein as crucial for Ebola virus to enter host cells

IGF1 plays key role in T-cell acute lymphoblastic leukemia

IGF1 plays key role in T-cell acute lymphoblastic leukemia

New advances in genomics, molecular diagnostics to be showcased at CAP 2011 meeting

New advances in genomics, molecular diagnostics to be showcased at CAP 2011 meeting

Johns Hopkins establishes Center for Personalized Cancer Medicine with Commonwealth Foundation gift

Johns Hopkins establishes Center for Personalized Cancer Medicine with Commonwealth Foundation gift

Modified Ecstasy could be effective against cancer: Study

Modified Ecstasy could be effective against cancer: Study

Uppsala University to lead new advanced cancer study

Uppsala University to lead new advanced cancer study

EMA accepts Merck and ARIAD's MAA for ridaforolimus to treat metastatic bone sarcomas

EMA accepts Merck and ARIAD's MAA for ridaforolimus to treat metastatic bone sarcomas

New leukemia drug in early clinical testing offers some clues for better treatment

New leukemia drug in early clinical testing offers some clues for better treatment

Premera, Cord Blood America partner to offer discount on stem cell collection services

Premera, Cord Blood America partner to offer discount on stem cell collection services

Clinical trials to evaluate and validate infrastructure of P-medicine consortium

Clinical trials to evaluate and validate infrastructure of P-medicine consortium

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.